Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: Its correlation with FLT3

Neoplasma

Volumn 60, Issue 6, 2013, Pages 666-675

  Mehta, S V ^a   Shukla, S N ^a   Vora, H H ^a  

^a GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

AML; Aplastic anemia; Bcl2; Flow cytometry; FLT3; MDS; PCR; RTPCR

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; CD135 ANTIGEN; CD19 ANTIGEN; CD2 ANTIGEN; CD22 ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD79A ANTIGEN; MESSENGER RNA; MICROSOMAL AMINOPEPTIDASE; MYELOPEROXIDASE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; RETINOIC ACID; STEM CELL FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; FLT3 PROTEIN, HUMAN; ORGANOARSENIC DERIVATIVE; OXIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FLOW CYTOMETRY; GENE DUPLICATION; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MYELOBLAST; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; POINT MUTATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; DRUG RESISTANCE; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TANDEM REPEAT;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; OXIDES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TANDEM REPEAT SEQUENCES; TRETINOIN; YOUNG ADULT;

EID: 84887547251     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_085     Document Type: Article

References (35)

1. HEEG S, WALLER CF. Cytogenetic and molecular aberrations as predictive biomarkers in acute myeloid leukemia. Biomarkers in Oncology 2013; 119-130. http://dx.doi.org/10.1007/978-1-4419-9755-5_6
2. YANG J, SCHIFFER CA. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized? Expert Review of Hematology 2012; 5: 395-407. http://dx.doi.org/10.1586/ehm.12.32
3. GUINN BA, MOHAMEDALI A, MILLS KI, CZEPULKOWSKI B, SCHMITT M et al. Leukemia associated antigens: Their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia. Biomarker Insights 2007; 2: 69-79.
4. TESTA U, RICCIONI R. Deregulation of apoptosis in acute myeloid leukemia. Haematologica 2007; 92: 81-94. http://dx.doi.org/10.3324/haematol.10279
5. POETA GD, VENDITTI A, PRINCIPE M, MAURILLO L, BUCCISANO F et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 2003; 101: 2125-2131. http://dx.doi.org/10.1182/blood-2002-06-1714
6. DASH P. Apoptosis-Basic Medical Sciences. Available from www.sgul.ac.uk/dept/immunology/~dash.
7. PARKER JE, MUFTI GJ, RASOOL F, MIJOVIC A, DEVEREUX S et al. The role of apoptosis, proliferation and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938.
8. LICHT J, STERNBERG D. The molecular pathology of acute myeloid leukemia. Hematology 2005; 137-142. http://dx.doi.org/10.1182/asheducation-2005.1.137
9. BENE MC, CASTOLDI G, KNAPP W, LUDWIG W, MATUTES E et al. Proposals for the immunological classification of acute leukemias. European group for the immunological characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786.
10. MEHTA SV, SHUKLA SN, VORA HH. Comprehensive FLT3 analysis in Indian Acute Myeloid Leukemia. J Blood Lymph 2012; 2. http://dx.doi.org/10.4172/2165-7831.1000102
11. VORA HH, SHUKLA SN, BRAHMBHATT BV, MEHTA SV, PATEL NA et al. Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia. Asian Pacific Journal of Clinical Oncology 2010; 6: 306-319. http://dx.doi.org/10.1111/j.1743-7563.2010.01322.x
12. ARMSTRONG SA, MABON ME, SILVERMAN LB, LI A, GRIBBEN JG et al. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 2004; 103: 3544-3546. http://dx.doi.org/10.1182/blood-2003-07-2441
13. SAHU G, JENA RK. Clinical significance of p53 and Bcl-2 in acute myeloid leukemia patients of eastern India. Hematology Reports 2011; 3: e28. http://dx.doi.org/10.4081/hr.2011.e28
14. ZHAO Z, ZUBER J, DIAZ-FLORES E, LINTAULT L, KOGAN SC et al. p53 loss promotes acute myeloid leukemia by enabling aberrant self-remowal. Genes & Development 2010; 24: 1389-1402. http://dx.doi.org/10.1101/gad.1940710
15. CAMPOS L, SABIDO O, RONAULT J, GUYOTAT D. Effects of BCL-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994; 84: 595-600.
16. LAURIA F, RASPADORI D, RONDELLI D, VENTURA MA, FLACCHINI M et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 1997; 11: 2075-2078. http://dx.doi.org/10.1038/sj.leu.2400854
17. BRADBURY DA, RUSSELL NH. Comparative quantitative expression of bcl-2 by normal and leukemic myeloid cells. Br J Haematol 1995; 91: 374-379. http://dx.doi.org/10.1111/j.1365-2141.1995.tb05306.x
18. VENDITTI A, POETA GD, MAURILLO L, BUCCISANO F, PRINCIPE MI et al. Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. Haematologica 2004; 89: 934-939.
19. IRISH JM, ANENSEN N, HOVLAND R, SKAVLAND J, BORRESEN-DALE AL et al. FLT3 Y591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p53. Blood 2007; 109: 2589-2596. http://dx.doi.org/10.1182/blood-2006-02-004234
20. KORNBLAU SM, THALL PF, ESTROV Z, WALTERSCHEID M, PATEL S et al. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clinical Cancer Research 1999; 5: 1758-1766.
21. MAUNG ZT, MACLEAN FR, REID MM, PEARSON AD, PROCTOR SJ et al. The relationship between bcl-2 expression and response to chemotherapy in acute leukemia. Br J Haematol 1994; 88: 105-109. http://dx.doi.org/10.1111/j.1365-2141.1994.tb04984.x
22. BENSI L, LONGO R, VECCHI A, MESSORA C, GARAGNANI L et al. BCL-2 oncoprotein expression in acute myeloid leukemia. Haematologica 1995; 80: 98-102.
23. CAMPOS L, ROUAULT JP, SABIDO O, ORIOL P, ROUBI N et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
24. TZIFI F, ECONOMOPOOULOU C, GOURGIOTIS D, ARDAVANIS A, PAPAGEORGIOU S et al. The role of Bcl2 family of apoptosis regulator proteins in acute and chronic leukemias. Advances in Hematology 2012. http://dx.doi.org/10.1155/2012/524308
25. TAMM I, RICHTER S, OLTERSDORF D et al. High expression levels of X-linked inhibitor of apoptosis protein and Survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clinical cancer research 2004; 10: 3737-3744. http://dx.doi.org/10.1158/1078-0432.CCR-03-0642
26. ANDREEFF M, JIANG S, ZHANG X, KONOPLEVA M, ESTROV Z et al. Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia 1999; 13: 1881-92. http://dx.doi.org/10.1038/sj.leu.2401573
27. BRADBURY DA, ALDINGTON S, ZHU YM, RUSSELL NH. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression. Br J Haematol 1996; 94: 671-675. http://dx.doi.org/10.1046/j.1365-2141.1996.d01-1838.x
28. PISANI F, DEL POETA G, ARONICA G, VENDITTI A, CARAVITA T et al. In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. Ann Hematol 1997; 75: 145-147. http://dx.doi.org/10.1007/s002770050332
29. LISOVSKY M, ESTROV Z, ZHANG X, CONSOLI U, SANCHEZ-WILLIAMS G et al. FLT3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996; 88: 3987-3997.
30. CHANG H, SALMA F, YI QL, PATTERSON B, BRIEN B et al. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leukemia Research 2004; 28: 43-48. http://dx.doi.org/10.1016/S0145-2126(03)00180-2
31. MESHINCHI S, ARCECI RJ. Prognostic factors and risk based therapy in pediatric acute myeloid leukemia. The Oncologist 2007; 12: 341-355. http://dx.doi.org/10.1634/theoncologist.12-3-341
32. AMIN HM, YANG Y, SHEN Y, ESTEY EH, GILES FJ et al. Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia 2005; 19: 1567-1572. http://dx.doi.org/10.1038/sj.leu.2403876
33. CALLERA F, GARCIA AB, FALCAO RP. Fas-mediated apoptosis with normal expression of bcl-2 and p53 in lymphocytes from aplastic anemia. Br J Haematol 1998; 100: 698-703. http://dx.doi.org/10.1046/j.1365-2141.1998.00625.x
34. ISMAIL M, GIBSON FM, GORDON-SMITH EC, RUTHERFORD TR. Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen. British Journal of Hematology 2001; 113: 706-712. http://dx.doi.org/10.1046/j.1365-2141.2001.02810.x
35. KUROTAKI H, TSUSHIMA Y, NAGAI K, YAGIHASHI S. Apoptosis, bcl-2 expression and p53 accummulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta haematol 2000; 102: 115-123. http://dx.doi.org/10.1159/000040984